<- Go Home
Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
Market Cap
$12.3B
Volume
354.9K
Cash and Equivalents
$292.7M
EBITDA
-$321.1M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$1.2B
Profit Margin
91.48%
52 Week High
$615.00
52 Week Low
$393.61
Dividend
N/A
Price / Book Value
23.44
Price / Earnings
-37.39
Price / Tangible Book Value
23.76
Enterprise Value
$11.8B
Enterprise Value / EBITDA
-36.99
Operating Income
-$322.6M
Return on Equity
53.31%
Return on Assets
-17.84
Cash and Short Term Investments
$838.8M
Debt
$347.8M
Equity
$523.7M
Revenue
$1.3B
Unlevered FCF
-$62.5M
Sector
Biotechnology
Category
N/A